Program Augments Existing Patient Advocacy and Professional Society Donations
to Non-Profit Organizations Aligned with Corporate Values
Deadline for Applications is September 16th, 2024
SOUTH SAN FRANCISCO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the Cytokinetics Corporate Giving Program. The program provides charitable donations to eligible non-profit organizations in the United States to support diversity in science education, equitable healthcare initiatives for cardiovascular disease and certain essential services for local and at-risk communities.
“For more than 25 years, our company has proudly championed patient advocacy, diversity, equity and inclusion initiatives, as well as research in our therapeutic focus areas of interest, and we have provided funding to non-profit organizations devoted to our shared mission,” said Diane Weiser, Cytokinetics’ Senior Vice President, Corporate Affairs. “We are pleased to now evolve our Corporate Giving Program to align with our maturing Corporate Responsibility interests and to provide additional support for an expanded array of giving priorities to make meaningful and lasting impact for stakeholders.”
The Cytokinetics Corporate Giving Program consists of individual charitable donations up to $20,000 for qualified 501(c)(3) organizations in the United States that are neither engaged, nor directly involved in the practice of healthcare. Specifically, the program will provide funding to organizations with initiatives focused on diversity in science education and certain essential services for local and at-risk communities in the San Francisco Bay Area and Greater Philadelphia Region. Additionally, it will support eligible organizations dedicated to health equity initiatives in cardiovascular disease across the United States. Applications may now be submitted online at https://www.cybergrants.com/Cytokinetics/corporate_giving_eligibility. The deadline to apply for the Cytokinetics Corporate Giving Program is September 16, 2024. For more information on the program, including eligibility details, guidelines and specifics, visit https://cytokinetics.com/responsibility/grants-and-giving-programs/corporate-giving-program/.
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
Source: Cytokinetics, Incorporated
